Cannabinoid Receptor Agonists in Cancer: Beyond Palliative Care to Potential Anti-Tumor Effects | Research

The takeaway

A review found that cannabinoids showed predominantly inhibitory effects on tumor growth, migration, angiogenesis, and metastasis in preclinical studies, suggesting potential as curative agents beyond their established palliative uses.

Read this if you are interested in whether cannabinoids could fight cancer beyond managing symptoms.

Predominantly inhibitory effects on tumor growth, migration, angiogenesis, and metastasis

What the researchers found

This review examined the growing evidence for cannabinoids in cancer treatment, covering both established palliative uses and emerging anti-tumor evidence.

Preclinical studies showed that cannabinoid receptor agonists can limit cell proliferation and induce tumor-selective cell death. Predominantly inhibitory effects were described on tumor growth, migration, blood vessel formation (angiogenesis), metastasis, and inflammation.

However, the review noted a complicating factor: synthetic cannabinoids could also have pro-tumor effects in living organisms due to their immunosuppressive properties, creating a tension between anti-tumor and immune-suppressive effects.

The authors suggested that cannabinoid receptor agonists expressed by tumor cells may offer a novel therapeutic strategy and proposed exploring cannabinoids not just as palliative agents but as potential curative treatments.

Why it matters

While cannabinoids have been used for cancer-related symptoms (nausea, pain, appetite), the preclinical evidence for direct anti-tumor effects suggested a fundamentally different role in cancer treatment.

The numbers in context

The review covered multiple cannabinoid types and cancer models. Inhibitory effects were described on tumor growth, migration, angiogenesis, metastasis, and inflammation.

How the study worked

Narrative review of preclinical research on cannabinoids and cancer, covering anti-proliferative effects, apoptosis induction, anti-angiogenic properties, anti-metastatic effects, and immunological considerations.

What this study cannot tell us

Evidence was primarily preclinical (cell culture and animal studies). The immunosuppressive properties of cannabinoids could theoretically promote tumor survival. Human cancer is far more complex than animal models suggest.

How to read the evidence

Review of preclinical evidence. Anti-tumor effects demonstrated in cell culture and animal models but not validated in human clinical trials.

When this study was published

Published in 2009. Clinical trials of cannabinoids as anti-cancer agents have proceeded slowly, with most human evidence still limited to palliative applications.

The bigger picture

The idea that cannabinoids might fight cancer directly, not just manage symptoms, has generated both scientific interest and public excitement. While preclinical evidence was growing in 2009, translating these findings to human cancer treatment has proven challenging.

Questions still open

Can anti-tumor effects be achieved at doses tolerable in humans? How can the tension between anti-tumor and immunosuppressive effects be managed? Which cancer types are most responsive to cannabinoid treatment?

Common questions

Can cannabinoids cure cancer?

Preclinical studies showed cannabinoids can kill cancer cells and inhibit tumor growth in lab settings. However, these results have not been confirmed in human clinical trials. The gap between cell culture effects and human cancer treatment is substantial.

Why might cannabinoids both fight and promote tumors?

Cannabinoids can directly kill tumor cells and inhibit their growth, but they also suppress immune function. Since the immune system helps fight cancer, immunosuppression could theoretically allow some tumors to grow. The net effect likely depends on cancer type and specific cannabinoid used.

Read the original research

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.

Best practice & research. Clinical endocrinology & metabolism, 23(1), 117-31

View on PubMed ↗Publisher’s paper ↗

Citation

Pisanti, Simona; Malfitano, Anna Maria; Grimaldi, Claudia; Santoro, Antonietta; Gazzerro, Patrizia; Laezza, Chiara; Bifulco, Maurizio. (2009). Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.. Best practice & research. Clinical endocrinology & metabolism, 23(1), 117-31. https://doi.org/10.1016/j.beem.2009.02.001